SlideShare a Scribd company logo
SURVIVAL OF LUNG CANCER PATIENTS
AFTER LOBECTOMIES WAS SIGNIFICANTLY
SUPERIOR IN COMPARISON WITH LUNG
CANCER PATIENTS AFTER
PNEUMONECTOMIES
Kshivets Oleg, MD, PhD
Surgery Department, Roshal Hospital, Roshal,
Moscow, Russia
ABSTRACT
OBJECTIVE: This study aimed to determine surgery type influence for 5-year survival (5YS) of non-small cell lung cancer (LC) patients (LCP) after complete en
block (R0) lobectomies and pneumonectomies.
METHODS: We analyzed data of 765 consecutive patients (age=57.6±8.3 years; tumor size=4.1±2.4 cm) radically operated (R0) and monitored in 1985-2022
(m=659, f=106; bi/lobectomies=512, pneumonectomies=253, mediastinal lymph node dissection=765; combined procedures with resection of trachea, carina,
atrium, aorta, VCS, vena azygos, pericardium, liver, diaphragm, ribs, esophagus=192; only surgery-S=616, adjuvant chemoimmunoradiotherapy-AT=149:
CAV/gemzar + cisplatin + thymalin/taktivin + radiotherapy 45-50Gy; T1=318, T2=255, T3=133, T4=59; N0=514, N1=131, N2=120, M0=765; G1=194, G2=241, G3=330;
squamous=417, adenocarcinoma=298, large cell=50; early LC=212, invasive LC=553. Multivariate Cox modeling, discriminant analysis, clustering, SEPATH, Monte
Carlo, bootstrap and neural networks computing were used to determine any significant dependence.
RESULTS: Overall life span (LS) was 2240.1±1751.6 days and cumulative 5-year survival (5YS) reached 72.8%, 10 years – 64.2%, 20 years – 42.9%. 499 LCP lived
more than 5 years (LS=3126.8±1540 days), 143 LCP – more than 10 years (LS=5083.3±1518.6 days).199 LCP died because of LC (LS=562.7±374.5 days). 5YS of LCP
after bi/lobectomies was significantly superior in comparison with LCP after pneumonectomies (77.6% vs.63.1%, P=0.00001 by log-rank test). AT significantly
improved 5YS (64.4% vs. 34.8%) (P=0.00003 by log-rank test) only for LCP with N1-2. Cox modeling displayed that 5YS of LCP significantly depended on: phase
transition (PT) early-invasive LC in terms of synergetics, PT N0—N12, cell ratio factors (ratio between cancer cells- CC and blood cells subpopulations), G1-3,
histology, glucose, AT, blood cell circuit, prothrombin index, heparin tolerance, recalcification time (P=0.000-0.038). 5YS of LCP after lobectomies (77.6%) was
significantly superior in comparison with LCP after pneumonectomies (63%) (P=0.00001 by log-rank test). Neural networks, genetic algorithm selection and
bootstrap simulation revealed relationships between 5YS and PT early-invasive LC (rank=1), PT N0—N12(rank=2), thrombocytes/CC (3), erythrocytes/CC (4),
eosinophils/CC (5), healthy cells/CC (6), segmented neutrophils/CC (7), lymphocytes/CC (8), monocytes/CC (9); stick neutrophils/CC (10), leucocytes/CC (11).
Correct prediction of 5YS was 100% by neural networks computing (area under ROC curve=1.0; error=0.0).
CONCLUSIONS: 5YS of LCP after radical procedures significantly depended on: 1) PT early-invasive cancer; 2) PT N0--N12; 3) cell ratio factors; 4) blood cell
circuit; 5) biochemical factors; 6) hemostasis system; 7) AT; 8) LC characteristics; 9) surgery type: lobectomy/pneumonectomy; 10) anthropometric data.
RADICAL PROCEDURES:
Bi/Lobectomies (R0)……………………………………..…….…….512
Pneumonectomies (R0)………………….………...........................253
Combined Procedures with Resection of Trachea, Carina,
Atrium, Aorta, VCS, Vena Azygos, Pericardium, Liver,
Diaphragm, Ribs, Esophagus (R0)……………...........................192
Mediastinal Lymphadenectomy………………………..………….765
DATA:
Males……………………………………………………………….....659
Females………..……………………………………….…................106
Age=57.6±8.3 years
Tumor Size=4.1±2.1 cm
Only Surgery.……………………………………………….............616
Adjuvant Chemoimmunoradiotherapy
(CAV/gemzar+cisplatin+thymalin/taktivin, 5-6 cycles+
Radiotherapy 45-50Gy)…………................................................149
STAGING:
T1……318 N0..….514 G1…………194
T2……255 N1…...131 G2…………241
T3……133 N2…...120 G3…………330
T4……..59 M0…..765
Adenocarcinoma………………………….….417
Squamos Cell Carcinoma…………………..228
Large Cell Carcinoma…………………...........50
Early Cancer……………………………...…...212
Invasive Cancer…………………………..…..553 .
SURVIVAL RATE:
Alive……………………………………….....511 (66.8%)
5-Year Survivors…………..……………….499 (65.2%)
10-Year Survivors………………………….143 (18.7%)
Losses……………………………………….199 (26%)
General Life Span=2240.1±1751.6 days
For 5-Year Survivors=3126.8±1540 days
For 10-Year Survivors=5083.3±1518.6 days
For Losses=562.7±374.5 days
Cumulative 5-Year Survival……………………..72.8%
Cumulative 10-Year Survival…………………....64.2%
Cumulative 20-Year Survival…………………....42.9%
GENERAL LUNG CANCER PATIENTS SURVIVAL AFTER COMPLETE
LOBECTOMIES/PNEUMONECTOMIES (KAPLAN-MEIER) (N=765):
Survival Function
5YS of LCP=72.8%; 10YS=64.2%; 20YS=42.9%.
Complete Censored
-5 0 5 10 15 20 25 30
Years after Surgery
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
Cumulative
Proportion
Surviving
RESULTS OF UNIVARIATE ANALYSIS OF PHASE TRANSITION EARLY—INVASIVE
CANCER IN PREDICTION OF LUNG CANCER PATIENTS SURVIVAL (N=765):
Cumulative Proportion Surviving (Kaplan-Meier)
5YS LCP with Early Cancer=100%; 5YS LCP with Invasive Cancer=62%;
P=0.0000 by Log-Rank Test.
Complete Censored
0 5 10 15 20 25 30 35
Years after Surgery
-0.2
0.0
0.2
0.4
0.6
0.8
1.0
Cumulative
Proportion
Surviving
LCP with Invasive Cancer
LCP with Early Cancer
RESULTS OF UNIVARIATE ANALYSIS OF PHASE TRANSITION N0—N1-2
IN PREDICTION OF LUNG CANCER PATIENTS SURVIVAL (N=765):
Cumulative Proportion Surviving (Kaplan-Meier)
5YS LCP with N0=86.8%; 5YS LCP with N12=43.4%;
P=0.0000 by Log-Rank Test.
Complete Censored
0 5 10 15 20 25 30 35
Years after Surgery
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
Cumulative
Proportion
Surviving
LCP with N12
LCP with N0
RESULTS OF UNIVARIATE ANALYSIS OF ADJUVANT
CHEMOIMMUNORADIOTHERAPY IN PREDICTION OF LUNG CANCER PATIENTS
SURVIVAL WITH N1-2 (N=251):
Cumulative Proportion Surviving (Kaplan-Meier)
LCP with N12 5YS LCP after Adjuvant Treatment=63.4%; 5YS after surgery along=34.8%;
P=0.00003 by Log-Rank Test.
Complete Censored
0 5 10 15 20 25 30
Years after Surgery
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
Cumulative
Proportion
Surviving
only Surgery
Adjuvant Chemoimmunoradiotherapy
RESULTS OF UNIVARIATE ANALYSIS OF SURGERY TYPE (LOBECTOMIES VS.
PNEUMONECTOMIES) IN PREDICTION OF LUNG CANCER PATIENTS SURVIVAL (N=765):
Cumulative Proportion Surviving (Kaplan-Meier)
5YS LCP after Lobectomies=77.6%; 5YS LCP after Pneumonectomies=63%;
P=0.00001 by Log-Rank Test.
Complete Censored
0 5 10 15 20 25 30 35
Years after Surgery
-0.1
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
Cumulative
Proportion
Surviving
LCP after Pneumonectomies
LCP after Lobectomies
RESULTS OF COX REGRESSION MODELING IN PREDICTION OF LUNG CANCER
PATIENTS SURVIVAL AFTER COMPLETE SURGERY (N=756):
Cox
Parameter
Estimate
Standard
Error
Chi-
square
P value
95%
Lower CL
95%
Upper CL
Hazard
Ratio
PT N0----N12 1.12860 0.144710 60.82492 0.000000 0.84497 1.4122293.091330
PT Early-Invasive LC -1.47064 0.289169 25.86488 0.000000 -2.03740 -0.9038810.229778
Histology 0.32311 0.083065 15.13080 0.000100 0.16030 0.4859111.381414
Heparin Tolerance 0.00334 0.000653 26.16087 0.000000 0.00206 0.0046221.003347
Recalcification Time -0.00395 0.001693 5.43911 0.019691 -0.00727 -0.0006300.996059
Prothrombin Index 0.03107 0.006560 22.43073 0.000002 0.01821 0.0439241.031555
AT -1.03805 0.196916 27.78926 0.000000 -1.42400 -0.6521060.354143
Leucocytes/CC -0.40957 0.150122 7.44318 0.006368 -0.70380 -0.1153320.663939
Segmented Neut/CC 0.43089 0.162072 7.06844 0.007845 0.11324 0.7485501.538633
Lymphocytes/CC 0.37542 0.172624 4.72960 0.029648 0.03708 0.7137521.455597
G1-3 0.31333 0.087560 12.80502 0.000346 0.14171 0.4849431.367969
Glucose -0.32171 0.077069 17.42452 0.000030 -0.47276 -0.1706540.724911
Thrombocytes tot 0.00055 0.000184 8.94820 0.002777 0.00019 0.0009131.000552
Erythrocytes tot -0.03595 0.016873 4.53860 0.033139 -0.06902 -0.0028760.964691
Age 0.01723 0.008588 4.02430 0.044849 0.00040 0.0340601.017377
RESULTS OF NEURAL NETWORKS COMPUTING IN PREDICTION OF LUNG
CANCER PATIENTS SURVIVAL AFTER COMPLETE SURGERY (N=698):
Corect Classification Rate=100%;
Error=0.000;
Area under ROC Curve=1.000.
Factors, LCP=698 Rank Sensitivity
Phase Transition Early—Invasive Cancer 1 28854
Phase Transition N0---N12 2 25420
Thrombocytes/Cancer Cells 3 11601
Erythrocytes/Cancer Cells 4 11414
Eosinophils/Cancer Cells 5 10658
Healthy Cells/Cancer Cells 6 8871
Segmented Neutrophils/Cancer Cells 7 7844
Lymphocytes/Cancer Cells 8 6416
Monocytes/Cancer Cells 9 5454
Stick Neutrophils/Cancer Cells 10 5353
Leucocytes/Cancer Cells 11 4075
RESULTS OF BOOTSTRAP SIMULATION IN PREDICTION OF
LUNG CANCER PATIENTS SURVIVAL AFTER SURGERY (N=698):
Bootstrap Simulation n=698
Significant Factors
(Number of Samples=3333)
Rank Kendal
Tau-A
P<
Healthy Cells/Cancer Cells 1 -0.297 0.000
Erythrocytes/Cancer Cells 2 -0.293 0.000
Lymphocytes/Cancer Cells 3 -0.287 0.000
Thrombocytes/Cancer Cells 4 -0.268 0.000
Leucocytes/Cancer Cells 5 -0.258 0.000
Segmented Neutrophils/Cancer Cells 6 -0.208 0.000
Tumor Size 7 0.174 0.000
Phase Transition Early-Invasive Cancer 8 -0.163 0.000
Phase Transition N0---N12 9 -0.158 0.000
T1-4 10 0.151 0.000
Prothrombin Index 11 0.141 0.000
Lymphocytes tot 12 -0.140 0.000
Erythrocytes tot 13 -0.138 0.000
Monocytes/Cancer Cells 14 -0.115 0.000
Segmented Neutrophils% 15 0.102 0.000
G1-3 16 0.090 0.001
Lymphocytes% 17 -0.089 0.001
Weight 18 -0.088 0.001
ESS 19 0.086 0.01
Pneumonectomies/Lobectomies 20 -0.067 0.01
Glucose 21 -0.060 0.05
Heparin Tolerance 22 0.060 0.05
Eosinophils/Cancer Cells 23 -0.060 0.05
Eosinophils% 24 -0.055 0.05
RESULTS OF KOHONEN SELF-ORGANIZING NEURAL NETWORKS COMPUTING IN
PREDICTION OF LUNG CANCER PATIENTS SURVIVAL AFTER SURGERY (N=698):
LUNG CANCER DYNAMICS:
PROGNOSTIC SEPATH-MODEL OF LUNG CANCER
PATIENTS SURVIVAL AFTER SURGERY (N=698):
5YS OF LCP AFTER RADICAL
PROCEDURES SIGNIFICANTLY
DEPENDED ON:
1) PHASE TRANSITION EARLY-INVASIVE
CANCER;
2) PHASE TRANSITION N0--N12;
3) CELL RATIO FACTORS;
4) BLOOD CELL CIRCUIT;
5) BIOCHEMICAL FACTORS;
6) HEMOSTASIS SYSTEM;
7) ADJUVANT TREATMENT;
8) LC CHARACTERISTICS;
9) SURGERY TYPE:
LOBECTOMY/PNEUMONECTOMY;
10) ANTHROPOMETRIC DATA.
Conclusion:
OLEG KSHIVETS, M.D.,PH.D.
CONSULTANT THORACIC, ABDOMINAL,
GENERAL SURGEON & SURGICAL
ONCOLOGIST
 e-mail: okshivets@yahoo.com
 skype: okshivets
 http: //www.ctsnet.org/home/okshivets

More Related Content

Similar to Survival of Lung Cancer Patients after Lobectomies was Significantly Superior in Comparison with Lung Cancer Patients after Pneumonectomies

Esophageal Cancer: Precise Prediction
Esophageal Cancer: Precise Prediction      Esophageal Cancer: Precise Prediction
Esophageal Cancer: Precise Prediction
Oleg Kshivets
 
Kshivets barcelona2019
Kshivets barcelona2019Kshivets barcelona2019
Kshivets barcelona2019
Oleg Kshivets
 
Kshivets ny2021aats
Kshivets ny2021aatsKshivets ny2021aats
Kshivets ny2021aats
Oleg Kshivets
 
Kshivets O. Esophageal and Cardioesophageal Cancer Surgery
Kshivets O. Esophageal and Cardioesophageal Cancer SurgeryKshivets O. Esophageal and Cardioesophageal Cancer Surgery
Kshivets O. Esophageal and Cardioesophageal Cancer Surgery
Oleg Kshivets
 
Kshivets chicago2016
Kshivets chicago2016Kshivets chicago2016
Kshivets chicago2016
Oleg Kshivets
 
Kshivets yokohama iaslc2017
Kshivets yokohama iaslc2017Kshivets yokohama iaslc2017
Kshivets yokohama iaslc2017
Oleg Kshivets
 
Kshivets Hong Kong Sydney2020
Kshivets Hong Kong Sydney2020Kshivets Hong Kong Sydney2020
Kshivets Hong Kong Sydney2020
Oleg Kshivets
 
Kshivets O. Local Advanced Lung Cancer Surgery
Kshivets O. Local Advanced Lung Cancer Surgery Kshivets O. Local Advanced Lung Cancer Surgery
Kshivets O. Local Advanced Lung Cancer Surgery
Oleg Kshivets
 
Kshivets milan2014
Kshivets milan2014Kshivets milan2014
Kshivets milan2014
Oleg Kshivets
 
Kshivets esmo2021
Kshivets esmo2021Kshivets esmo2021
Kshivets esmo2021
Oleg Kshivets
 
Lung Cancer: Precise Prediction
Lung Cancer: Precise PredictionLung Cancer: Precise Prediction
Lung Cancer: Precise Prediction
Oleg Kshivets
 
Kshivets_ELCC2023.pdf
Kshivets_ELCC2023.pdfKshivets_ELCC2023.pdf
Kshivets_ELCC2023.pdf
Oleg Kshivets
 
Kshivets_ELCC2023.pdf
Kshivets_ELCC2023.pdfKshivets_ELCC2023.pdf
Kshivets_ELCC2023.pdf
Oleg Kshivets
 
Esophageal Cancer: Artificial Intelligence, Synergetics, Complex System Analy...
Esophageal Cancer: Artificial Intelligence, Synergetics, Complex System Analy...Esophageal Cancer: Artificial Intelligence, Synergetics, Complex System Analy...
Esophageal Cancer: Artificial Intelligence, Synergetics, Complex System Analy...
Oleg Kshivets
 
Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...
Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...
Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...
Oleg Kshivets
 
Kshivets elcc2022
Kshivets elcc2022Kshivets elcc2022
Kshivets elcc2022
Oleg Kshivets
 
Combined Esophagogastrectomies: Survival Outcomes in Patients with Local Adva...
Combined Esophagogastrectomies: Survival Outcomes in Patients with Local Adva...Combined Esophagogastrectomies: Survival Outcomes in Patients with Local Adva...
Combined Esophagogastrectomies: Survival Outcomes in Patients with Local Adva...
Oleg Kshivets
 
Kshivets eacts milan2018
Kshivets eacts milan2018Kshivets eacts milan2018
Kshivets eacts milan2018
Oleg Kshivets
 
Lung Cancer: 10-Year Survival
Lung Cancer: 10-Year Survival           Lung Cancer: 10-Year Survival
Lung Cancer: 10-Year Survival
Oleg Kshivets
 
Kshivets barcelona2017
Kshivets barcelona2017Kshivets barcelona2017
Kshivets barcelona2017
Oleg Kshivets
 

Similar to Survival of Lung Cancer Patients after Lobectomies was Significantly Superior in Comparison with Lung Cancer Patients after Pneumonectomies (20)

Esophageal Cancer: Precise Prediction
Esophageal Cancer: Precise Prediction      Esophageal Cancer: Precise Prediction
Esophageal Cancer: Precise Prediction
 
Kshivets barcelona2019
Kshivets barcelona2019Kshivets barcelona2019
Kshivets barcelona2019
 
Kshivets ny2021aats
Kshivets ny2021aatsKshivets ny2021aats
Kshivets ny2021aats
 
Kshivets O. Esophageal and Cardioesophageal Cancer Surgery
Kshivets O. Esophageal and Cardioesophageal Cancer SurgeryKshivets O. Esophageal and Cardioesophageal Cancer Surgery
Kshivets O. Esophageal and Cardioesophageal Cancer Surgery
 
Kshivets chicago2016
Kshivets chicago2016Kshivets chicago2016
Kshivets chicago2016
 
Kshivets yokohama iaslc2017
Kshivets yokohama iaslc2017Kshivets yokohama iaslc2017
Kshivets yokohama iaslc2017
 
Kshivets Hong Kong Sydney2020
Kshivets Hong Kong Sydney2020Kshivets Hong Kong Sydney2020
Kshivets Hong Kong Sydney2020
 
Kshivets O. Local Advanced Lung Cancer Surgery
Kshivets O. Local Advanced Lung Cancer Surgery Kshivets O. Local Advanced Lung Cancer Surgery
Kshivets O. Local Advanced Lung Cancer Surgery
 
Kshivets milan2014
Kshivets milan2014Kshivets milan2014
Kshivets milan2014
 
Kshivets esmo2021
Kshivets esmo2021Kshivets esmo2021
Kshivets esmo2021
 
Lung Cancer: Precise Prediction
Lung Cancer: Precise PredictionLung Cancer: Precise Prediction
Lung Cancer: Precise Prediction
 
Kshivets_ELCC2023.pdf
Kshivets_ELCC2023.pdfKshivets_ELCC2023.pdf
Kshivets_ELCC2023.pdf
 
Kshivets_ELCC2023.pdf
Kshivets_ELCC2023.pdfKshivets_ELCC2023.pdf
Kshivets_ELCC2023.pdf
 
Esophageal Cancer: Artificial Intelligence, Synergetics, Complex System Analy...
Esophageal Cancer: Artificial Intelligence, Synergetics, Complex System Analy...Esophageal Cancer: Artificial Intelligence, Synergetics, Complex System Analy...
Esophageal Cancer: Artificial Intelligence, Synergetics, Complex System Analy...
 
Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...
Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...
Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...
 
Kshivets elcc2022
Kshivets elcc2022Kshivets elcc2022
Kshivets elcc2022
 
Combined Esophagogastrectomies: Survival Outcomes in Patients with Local Adva...
Combined Esophagogastrectomies: Survival Outcomes in Patients with Local Adva...Combined Esophagogastrectomies: Survival Outcomes in Patients with Local Adva...
Combined Esophagogastrectomies: Survival Outcomes in Patients with Local Adva...
 
Kshivets eacts milan2018
Kshivets eacts milan2018Kshivets eacts milan2018
Kshivets eacts milan2018
 
Lung Cancer: 10-Year Survival
Lung Cancer: 10-Year Survival           Lung Cancer: 10-Year Survival
Lung Cancer: 10-Year Survival
 
Kshivets barcelona2017
Kshivets barcelona2017Kshivets barcelona2017
Kshivets barcelona2017
 

More from Oleg Kshivets

Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...
Oleg Kshivets
 
Gastric Cancer: Сlinical Implementation of Artificial Intelligence, Synergeti...
Gastric Cancer: Сlinical Implementation of Artificial Intelligence, Synergeti...Gastric Cancer: Сlinical Implementation of Artificial Intelligence, Synergeti...
Gastric Cancer: Сlinical Implementation of Artificial Intelligence, Synergeti...
Oleg Kshivets
 
Local Advanced Esophageal Cancer (T3-4N0-2M0): Artificial Intelligence, Syner...
Local Advanced Esophageal Cancer (T3-4N0-2M0): Artificial Intelligence, Syner...Local Advanced Esophageal Cancer (T3-4N0-2M0): Artificial Intelligence, Syner...
Local Advanced Esophageal Cancer (T3-4N0-2M0): Artificial Intelligence, Syner...
Oleg Kshivets
 
Kshivets Oleg Optimization of Management for Esophageal Cancer Patients (T1-...
Kshivets Oleg  Optimization of Management for Esophageal Cancer Patients (T1-...Kshivets Oleg  Optimization of Management for Esophageal Cancer Patients (T1-...
Kshivets Oleg Optimization of Management for Esophageal Cancer Patients (T1-...
Oleg Kshivets
 
Kshivets_IASLC_Singapore2023.pdf
Kshivets_IASLC_Singapore2023.pdfKshivets_IASLC_Singapore2023.pdf
Kshivets_IASLC_Singapore2023.pdf
Oleg Kshivets
 
KshivetsWSCTS2023_Brazil.pdf
KshivetsWSCTS2023_Brazil.pdfKshivetsWSCTS2023_Brazil.pdf
KshivetsWSCTS2023_Brazil.pdf
Oleg Kshivets
 
KshivetsWSCTS2023_Brazil.pdf
KshivetsWSCTS2023_Brazil.pdfKshivetsWSCTS2023_Brazil.pdf
KshivetsWSCTS2023_Brazil.pdf
Oleg Kshivets
 
KshivetsWSCTS2023_Brazil.pdf
KshivetsWSCTS2023_Brazil.pdfKshivetsWSCTS2023_Brazil.pdf
KshivetsWSCTS2023_Brazil.pdf
Oleg Kshivets
 
Kshivets_WCGIC2023.pdf
Kshivets_WCGIC2023.pdfKshivets_WCGIC2023.pdf
Kshivets_WCGIC2023.pdf
Oleg Kshivets
 
Kshivets_SPB_WSCTS2022Lung.pdf
Kshivets_SPB_WSCTS2022Lung.pdfKshivets_SPB_WSCTS2022Lung.pdf
Kshivets_SPB_WSCTS2022Lung.pdf
Oleg Kshivets
 
Lung cancer cell dynamics significantly depended on blood cell circuit, bioch...
Lung cancer cell dynamics significantly depended on blood cell circuit, bioch...Lung cancer cell dynamics significantly depended on blood cell circuit, bioch...
Lung cancer cell dynamics significantly depended on blood cell circuit, bioch...
Oleg Kshivets
 
• Gastric cancer prognosis and cell ratio factors
•	Gastric cancer prognosis and cell ratio factors           •	Gastric cancer prognosis and cell ratio factors
• Gastric cancer prognosis and cell ratio factors
Oleg Kshivets
 
Kshivets gc 10_ys_wjarr-2021-0659
Kshivets gc 10_ys_wjarr-2021-0659Kshivets gc 10_ys_wjarr-2021-0659
Kshivets gc 10_ys_wjarr-2021-0659
Oleg Kshivets
 
Kshivets lc10 ys_wjarr
Kshivets lc10 ys_wjarrKshivets lc10 ys_wjarr
Kshivets lc10 ys_wjarr
Oleg Kshivets
 
Kshivets eso10 y2021
Kshivets eso10 y2021Kshivets eso10 y2021
Kshivets eso10 y2021
Oleg Kshivets
 
2021 esmo world_gi_poster_kshivets
2021 esmo world_gi_poster_kshivets2021 esmo world_gi_poster_kshivets
2021 esmo world_gi_poster_kshivets
Oleg Kshivets
 
Kshivets iaslc singapore2020
Kshivets iaslc singapore2020Kshivets iaslc singapore2020
Kshivets iaslc singapore2020
Oleg Kshivets
 

More from Oleg Kshivets (17)

Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...
 
Gastric Cancer: Сlinical Implementation of Artificial Intelligence, Synergeti...
Gastric Cancer: Сlinical Implementation of Artificial Intelligence, Synergeti...Gastric Cancer: Сlinical Implementation of Artificial Intelligence, Synergeti...
Gastric Cancer: Сlinical Implementation of Artificial Intelligence, Synergeti...
 
Local Advanced Esophageal Cancer (T3-4N0-2M0): Artificial Intelligence, Syner...
Local Advanced Esophageal Cancer (T3-4N0-2M0): Artificial Intelligence, Syner...Local Advanced Esophageal Cancer (T3-4N0-2M0): Artificial Intelligence, Syner...
Local Advanced Esophageal Cancer (T3-4N0-2M0): Artificial Intelligence, Syner...
 
Kshivets Oleg Optimization of Management for Esophageal Cancer Patients (T1-...
Kshivets Oleg  Optimization of Management for Esophageal Cancer Patients (T1-...Kshivets Oleg  Optimization of Management for Esophageal Cancer Patients (T1-...
Kshivets Oleg Optimization of Management for Esophageal Cancer Patients (T1-...
 
Kshivets_IASLC_Singapore2023.pdf
Kshivets_IASLC_Singapore2023.pdfKshivets_IASLC_Singapore2023.pdf
Kshivets_IASLC_Singapore2023.pdf
 
KshivetsWSCTS2023_Brazil.pdf
KshivetsWSCTS2023_Brazil.pdfKshivetsWSCTS2023_Brazil.pdf
KshivetsWSCTS2023_Brazil.pdf
 
KshivetsWSCTS2023_Brazil.pdf
KshivetsWSCTS2023_Brazil.pdfKshivetsWSCTS2023_Brazil.pdf
KshivetsWSCTS2023_Brazil.pdf
 
KshivetsWSCTS2023_Brazil.pdf
KshivetsWSCTS2023_Brazil.pdfKshivetsWSCTS2023_Brazil.pdf
KshivetsWSCTS2023_Brazil.pdf
 
Kshivets_WCGIC2023.pdf
Kshivets_WCGIC2023.pdfKshivets_WCGIC2023.pdf
Kshivets_WCGIC2023.pdf
 
Kshivets_SPB_WSCTS2022Lung.pdf
Kshivets_SPB_WSCTS2022Lung.pdfKshivets_SPB_WSCTS2022Lung.pdf
Kshivets_SPB_WSCTS2022Lung.pdf
 
Lung cancer cell dynamics significantly depended on blood cell circuit, bioch...
Lung cancer cell dynamics significantly depended on blood cell circuit, bioch...Lung cancer cell dynamics significantly depended on blood cell circuit, bioch...
Lung cancer cell dynamics significantly depended on blood cell circuit, bioch...
 
• Gastric cancer prognosis and cell ratio factors
•	Gastric cancer prognosis and cell ratio factors           •	Gastric cancer prognosis and cell ratio factors
• Gastric cancer prognosis and cell ratio factors
 
Kshivets gc 10_ys_wjarr-2021-0659
Kshivets gc 10_ys_wjarr-2021-0659Kshivets gc 10_ys_wjarr-2021-0659
Kshivets gc 10_ys_wjarr-2021-0659
 
Kshivets lc10 ys_wjarr
Kshivets lc10 ys_wjarrKshivets lc10 ys_wjarr
Kshivets lc10 ys_wjarr
 
Kshivets eso10 y2021
Kshivets eso10 y2021Kshivets eso10 y2021
Kshivets eso10 y2021
 
2021 esmo world_gi_poster_kshivets
2021 esmo world_gi_poster_kshivets2021 esmo world_gi_poster_kshivets
2021 esmo world_gi_poster_kshivets
 
Kshivets iaslc singapore2020
Kshivets iaslc singapore2020Kshivets iaslc singapore2020
Kshivets iaslc singapore2020
 

Recently uploaded

RESPIRATORY DISEASES by bhavya kelavadiya
RESPIRATORY DISEASES by bhavya kelavadiyaRESPIRATORY DISEASES by bhavya kelavadiya
RESPIRATORY DISEASES by bhavya kelavadiya
Bhavyakelawadiya
 
5 Effective Homeopathic Medicines for Irregular Periods
5 Effective Homeopathic Medicines for Irregular Periods5 Effective Homeopathic Medicines for Irregular Periods
5 Effective Homeopathic Medicines for Irregular Periods
Dr. Deepika's Homeopathy - Gaur City
 
Hemodialysis: Chapter 6, Hemodialysis Adequacy and Dose - Dr.Gawad
Hemodialysis: Chapter 6, Hemodialysis Adequacy and Dose - Dr.GawadHemodialysis: Chapter 6, Hemodialysis Adequacy and Dose - Dr.Gawad
Hemodialysis: Chapter 6, Hemodialysis Adequacy and Dose - Dr.Gawad
NephroTube - Dr.Gawad
 
Osvaldo Bernardo Muchanga-GASTROINTESTINAL INFECTIONS AND GASTRITIS-2024.pdf
Osvaldo Bernardo Muchanga-GASTROINTESTINAL INFECTIONS AND GASTRITIS-2024.pdfOsvaldo Bernardo Muchanga-GASTROINTESTINAL INFECTIONS AND GASTRITIS-2024.pdf
Osvaldo Bernardo Muchanga-GASTROINTESTINAL INFECTIONS AND GASTRITIS-2024.pdf
Osvaldo Bernardo Muchanga
 
ENVIRONMENTAL SANITATION in community setting
ENVIRONMENTAL SANITATION in community settingENVIRONMENTAL SANITATION in community setting
ENVIRONMENTAL SANITATION in community setting
ShraddhaTamshettiwar
 
pharmacology for dummies free pdf download.pdf
pharmacology for dummies free pdf download.pdfpharmacology for dummies free pdf download.pdf
pharmacology for dummies free pdf download.pdf
KerlynIgnacio
 
anatomy of submandibular region presentation
anatomy of submandibular region presentationanatomy of submandibular region presentation
anatomy of submandibular region presentation
MalaM67
 
Breast cancer: Post menopausal endocrine therapy
Breast cancer: Post menopausal endocrine therapyBreast cancer: Post menopausal endocrine therapy
Breast cancer: Post menopausal endocrine therapy
Dr. Sumit KUMAR
 
Tele Optometry (kunj'sppt) / Basics of tele optometry.
Tele Optometry (kunj'sppt) / Basics of tele optometry.Tele Optometry (kunj'sppt) / Basics of tele optometry.
Tele Optometry (kunj'sppt) / Basics of tele optometry.
Kunj Vihari
 
Storyboard on Skin- Innovative Learning (M-pharm) 2nd sem. (Cosmetics)
Storyboard on Skin- Innovative Learning (M-pharm) 2nd sem. (Cosmetics)Storyboard on Skin- Innovative Learning (M-pharm) 2nd sem. (Cosmetics)
Storyboard on Skin- Innovative Learning (M-pharm) 2nd sem. (Cosmetics)
MuskanShingari
 
Spontaneous Bacterial Peritonitis - Pathogenesis , Clinical Features & Manage...
Spontaneous Bacterial Peritonitis - Pathogenesis , Clinical Features & Manage...Spontaneous Bacterial Peritonitis - Pathogenesis , Clinical Features & Manage...
Spontaneous Bacterial Peritonitis - Pathogenesis , Clinical Features & Manage...
Jim Jacob Roy
 
Call Girls Electronic City 🥰 Bangalore Call Girl No Advance Book Now
Call Girls Electronic City 🥰 Bangalore Call Girl No Advance Book NowCall Girls Electronic City 🥰 Bangalore Call Girl No Advance Book Now
Call Girls Electronic City 🥰 Bangalore Call Girl No Advance Book Now
saftyhealth48
 
Call Girl Pune 7339748667 Vip Call Girls Pune
Call Girl Pune 7339748667 Vip Call Girls PuneCall Girl Pune 7339748667 Vip Call Girls Pune
Call Girl Pune 7339748667 Vip Call Girls Pune
Mobile Problem
 
Microbiology & Parasitology Exercises Parts of the Microscope
Microbiology & Parasitology Exercises Parts of the MicroscopeMicrobiology & Parasitology Exercises Parts of the Microscope
Microbiology & Parasitology Exercises Parts of the Microscope
ThaShee2
 
Nutritional deficiency disorder in Child
Nutritional deficiency disorder in ChildNutritional deficiency disorder in Child
Nutritional deficiency disorder in Child
Bhavyakelawadiya
 
TEST BANK For Brunner and Suddarth's Textbook of Medical-Surgical Nursing, 14...
TEST BANK For Brunner and Suddarth's Textbook of Medical-Surgical Nursing, 14...TEST BANK For Brunner and Suddarth's Textbook of Medical-Surgical Nursing, 14...
TEST BANK For Brunner and Suddarth's Textbook of Medical-Surgical Nursing, 14...
Donc Test
 
pharmacy exam preparation for undergradute students.pptx
pharmacy exam preparation for undergradute students.pptxpharmacy exam preparation for undergradute students.pptx
pharmacy exam preparation for undergradute students.pptx
AdugnaWari
 
Selective α1-Blocker.pptx
Selective α1-Blocker.pptxSelective α1-Blocker.pptx
Selective α1-Blocker.pptx
Madhumita Dixit
 
Helminthiasis or Worm infestation in Children for Nursing students
Helminthiasis or Worm infestation in Children for Nursing studentsHelminthiasis or Worm infestation in Children for Nursing students
Helminthiasis or Worm infestation in Children for Nursing students
RAJU B N
 
acne vulgaris -Mpharm (2nd semester) Cosmetics and cosmeceuticals
acne vulgaris -Mpharm (2nd semester) Cosmetics and cosmeceuticalsacne vulgaris -Mpharm (2nd semester) Cosmetics and cosmeceuticals
acne vulgaris -Mpharm (2nd semester) Cosmetics and cosmeceuticals
MuskanShingari
 

Recently uploaded (20)

RESPIRATORY DISEASES by bhavya kelavadiya
RESPIRATORY DISEASES by bhavya kelavadiyaRESPIRATORY DISEASES by bhavya kelavadiya
RESPIRATORY DISEASES by bhavya kelavadiya
 
5 Effective Homeopathic Medicines for Irregular Periods
5 Effective Homeopathic Medicines for Irregular Periods5 Effective Homeopathic Medicines for Irregular Periods
5 Effective Homeopathic Medicines for Irregular Periods
 
Hemodialysis: Chapter 6, Hemodialysis Adequacy and Dose - Dr.Gawad
Hemodialysis: Chapter 6, Hemodialysis Adequacy and Dose - Dr.GawadHemodialysis: Chapter 6, Hemodialysis Adequacy and Dose - Dr.Gawad
Hemodialysis: Chapter 6, Hemodialysis Adequacy and Dose - Dr.Gawad
 
Osvaldo Bernardo Muchanga-GASTROINTESTINAL INFECTIONS AND GASTRITIS-2024.pdf
Osvaldo Bernardo Muchanga-GASTROINTESTINAL INFECTIONS AND GASTRITIS-2024.pdfOsvaldo Bernardo Muchanga-GASTROINTESTINAL INFECTIONS AND GASTRITIS-2024.pdf
Osvaldo Bernardo Muchanga-GASTROINTESTINAL INFECTIONS AND GASTRITIS-2024.pdf
 
ENVIRONMENTAL SANITATION in community setting
ENVIRONMENTAL SANITATION in community settingENVIRONMENTAL SANITATION in community setting
ENVIRONMENTAL SANITATION in community setting
 
pharmacology for dummies free pdf download.pdf
pharmacology for dummies free pdf download.pdfpharmacology for dummies free pdf download.pdf
pharmacology for dummies free pdf download.pdf
 
anatomy of submandibular region presentation
anatomy of submandibular region presentationanatomy of submandibular region presentation
anatomy of submandibular region presentation
 
Breast cancer: Post menopausal endocrine therapy
Breast cancer: Post menopausal endocrine therapyBreast cancer: Post menopausal endocrine therapy
Breast cancer: Post menopausal endocrine therapy
 
Tele Optometry (kunj'sppt) / Basics of tele optometry.
Tele Optometry (kunj'sppt) / Basics of tele optometry.Tele Optometry (kunj'sppt) / Basics of tele optometry.
Tele Optometry (kunj'sppt) / Basics of tele optometry.
 
Storyboard on Skin- Innovative Learning (M-pharm) 2nd sem. (Cosmetics)
Storyboard on Skin- Innovative Learning (M-pharm) 2nd sem. (Cosmetics)Storyboard on Skin- Innovative Learning (M-pharm) 2nd sem. (Cosmetics)
Storyboard on Skin- Innovative Learning (M-pharm) 2nd sem. (Cosmetics)
 
Spontaneous Bacterial Peritonitis - Pathogenesis , Clinical Features & Manage...
Spontaneous Bacterial Peritonitis - Pathogenesis , Clinical Features & Manage...Spontaneous Bacterial Peritonitis - Pathogenesis , Clinical Features & Manage...
Spontaneous Bacterial Peritonitis - Pathogenesis , Clinical Features & Manage...
 
Call Girls Electronic City 🥰 Bangalore Call Girl No Advance Book Now
Call Girls Electronic City 🥰 Bangalore Call Girl No Advance Book NowCall Girls Electronic City 🥰 Bangalore Call Girl No Advance Book Now
Call Girls Electronic City 🥰 Bangalore Call Girl No Advance Book Now
 
Call Girl Pune 7339748667 Vip Call Girls Pune
Call Girl Pune 7339748667 Vip Call Girls PuneCall Girl Pune 7339748667 Vip Call Girls Pune
Call Girl Pune 7339748667 Vip Call Girls Pune
 
Microbiology & Parasitology Exercises Parts of the Microscope
Microbiology & Parasitology Exercises Parts of the MicroscopeMicrobiology & Parasitology Exercises Parts of the Microscope
Microbiology & Parasitology Exercises Parts of the Microscope
 
Nutritional deficiency disorder in Child
Nutritional deficiency disorder in ChildNutritional deficiency disorder in Child
Nutritional deficiency disorder in Child
 
TEST BANK For Brunner and Suddarth's Textbook of Medical-Surgical Nursing, 14...
TEST BANK For Brunner and Suddarth's Textbook of Medical-Surgical Nursing, 14...TEST BANK For Brunner and Suddarth's Textbook of Medical-Surgical Nursing, 14...
TEST BANK For Brunner and Suddarth's Textbook of Medical-Surgical Nursing, 14...
 
pharmacy exam preparation for undergradute students.pptx
pharmacy exam preparation for undergradute students.pptxpharmacy exam preparation for undergradute students.pptx
pharmacy exam preparation for undergradute students.pptx
 
Selective α1-Blocker.pptx
Selective α1-Blocker.pptxSelective α1-Blocker.pptx
Selective α1-Blocker.pptx
 
Helminthiasis or Worm infestation in Children for Nursing students
Helminthiasis or Worm infestation in Children for Nursing studentsHelminthiasis or Worm infestation in Children for Nursing students
Helminthiasis or Worm infestation in Children for Nursing students
 
acne vulgaris -Mpharm (2nd semester) Cosmetics and cosmeceuticals
acne vulgaris -Mpharm (2nd semester) Cosmetics and cosmeceuticalsacne vulgaris -Mpharm (2nd semester) Cosmetics and cosmeceuticals
acne vulgaris -Mpharm (2nd semester) Cosmetics and cosmeceuticals
 

Survival of Lung Cancer Patients after Lobectomies was Significantly Superior in Comparison with Lung Cancer Patients after Pneumonectomies

  • 1. SURVIVAL OF LUNG CANCER PATIENTS AFTER LOBECTOMIES WAS SIGNIFICANTLY SUPERIOR IN COMPARISON WITH LUNG CANCER PATIENTS AFTER PNEUMONECTOMIES Kshivets Oleg, MD, PhD Surgery Department, Roshal Hospital, Roshal, Moscow, Russia
  • 2. ABSTRACT OBJECTIVE: This study aimed to determine surgery type influence for 5-year survival (5YS) of non-small cell lung cancer (LC) patients (LCP) after complete en block (R0) lobectomies and pneumonectomies. METHODS: We analyzed data of 765 consecutive patients (age=57.6±8.3 years; tumor size=4.1±2.4 cm) radically operated (R0) and monitored in 1985-2022 (m=659, f=106; bi/lobectomies=512, pneumonectomies=253, mediastinal lymph node dissection=765; combined procedures with resection of trachea, carina, atrium, aorta, VCS, vena azygos, pericardium, liver, diaphragm, ribs, esophagus=192; only surgery-S=616, adjuvant chemoimmunoradiotherapy-AT=149: CAV/gemzar + cisplatin + thymalin/taktivin + radiotherapy 45-50Gy; T1=318, T2=255, T3=133, T4=59; N0=514, N1=131, N2=120, M0=765; G1=194, G2=241, G3=330; squamous=417, adenocarcinoma=298, large cell=50; early LC=212, invasive LC=553. Multivariate Cox modeling, discriminant analysis, clustering, SEPATH, Monte Carlo, bootstrap and neural networks computing were used to determine any significant dependence. RESULTS: Overall life span (LS) was 2240.1±1751.6 days and cumulative 5-year survival (5YS) reached 72.8%, 10 years – 64.2%, 20 years – 42.9%. 499 LCP lived more than 5 years (LS=3126.8±1540 days), 143 LCP – more than 10 years (LS=5083.3±1518.6 days).199 LCP died because of LC (LS=562.7±374.5 days). 5YS of LCP after bi/lobectomies was significantly superior in comparison with LCP after pneumonectomies (77.6% vs.63.1%, P=0.00001 by log-rank test). AT significantly improved 5YS (64.4% vs. 34.8%) (P=0.00003 by log-rank test) only for LCP with N1-2. Cox modeling displayed that 5YS of LCP significantly depended on: phase transition (PT) early-invasive LC in terms of synergetics, PT N0—N12, cell ratio factors (ratio between cancer cells- CC and blood cells subpopulations), G1-3, histology, glucose, AT, blood cell circuit, prothrombin index, heparin tolerance, recalcification time (P=0.000-0.038). 5YS of LCP after lobectomies (77.6%) was significantly superior in comparison with LCP after pneumonectomies (63%) (P=0.00001 by log-rank test). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and PT early-invasive LC (rank=1), PT N0—N12(rank=2), thrombocytes/CC (3), erythrocytes/CC (4), eosinophils/CC (5), healthy cells/CC (6), segmented neutrophils/CC (7), lymphocytes/CC (8), monocytes/CC (9); stick neutrophils/CC (10), leucocytes/CC (11). Correct prediction of 5YS was 100% by neural networks computing (area under ROC curve=1.0; error=0.0). CONCLUSIONS: 5YS of LCP after radical procedures significantly depended on: 1) PT early-invasive cancer; 2) PT N0--N12; 3) cell ratio factors; 4) blood cell circuit; 5) biochemical factors; 6) hemostasis system; 7) AT; 8) LC characteristics; 9) surgery type: lobectomy/pneumonectomy; 10) anthropometric data.
  • 3. RADICAL PROCEDURES: Bi/Lobectomies (R0)……………………………………..…….…….512 Pneumonectomies (R0)………………….………...........................253 Combined Procedures with Resection of Trachea, Carina, Atrium, Aorta, VCS, Vena Azygos, Pericardium, Liver, Diaphragm, Ribs, Esophagus (R0)……………...........................192 Mediastinal Lymphadenectomy………………………..………….765
  • 4. DATA: Males……………………………………………………………….....659 Females………..……………………………………….…................106 Age=57.6±8.3 years Tumor Size=4.1±2.1 cm Only Surgery.……………………………………………….............616 Adjuvant Chemoimmunoradiotherapy (CAV/gemzar+cisplatin+thymalin/taktivin, 5-6 cycles+ Radiotherapy 45-50Gy)…………................................................149
  • 5. STAGING: T1……318 N0..….514 G1…………194 T2……255 N1…...131 G2…………241 T3……133 N2…...120 G3…………330 T4……..59 M0…..765 Adenocarcinoma………………………….….417 Squamos Cell Carcinoma…………………..228 Large Cell Carcinoma…………………...........50 Early Cancer……………………………...…...212 Invasive Cancer…………………………..…..553 .
  • 6. SURVIVAL RATE: Alive……………………………………….....511 (66.8%) 5-Year Survivors…………..……………….499 (65.2%) 10-Year Survivors………………………….143 (18.7%) Losses……………………………………….199 (26%) General Life Span=2240.1±1751.6 days For 5-Year Survivors=3126.8±1540 days For 10-Year Survivors=5083.3±1518.6 days For Losses=562.7±374.5 days Cumulative 5-Year Survival……………………..72.8% Cumulative 10-Year Survival…………………....64.2% Cumulative 20-Year Survival…………………....42.9%
  • 7. GENERAL LUNG CANCER PATIENTS SURVIVAL AFTER COMPLETE LOBECTOMIES/PNEUMONECTOMIES (KAPLAN-MEIER) (N=765): Survival Function 5YS of LCP=72.8%; 10YS=64.2%; 20YS=42.9%. Complete Censored -5 0 5 10 15 20 25 30 Years after Surgery 0.0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1.0 Cumulative Proportion Surviving
  • 8. RESULTS OF UNIVARIATE ANALYSIS OF PHASE TRANSITION EARLY—INVASIVE CANCER IN PREDICTION OF LUNG CANCER PATIENTS SURVIVAL (N=765): Cumulative Proportion Surviving (Kaplan-Meier) 5YS LCP with Early Cancer=100%; 5YS LCP with Invasive Cancer=62%; P=0.0000 by Log-Rank Test. Complete Censored 0 5 10 15 20 25 30 35 Years after Surgery -0.2 0.0 0.2 0.4 0.6 0.8 1.0 Cumulative Proportion Surviving LCP with Invasive Cancer LCP with Early Cancer
  • 9. RESULTS OF UNIVARIATE ANALYSIS OF PHASE TRANSITION N0—N1-2 IN PREDICTION OF LUNG CANCER PATIENTS SURVIVAL (N=765): Cumulative Proportion Surviving (Kaplan-Meier) 5YS LCP with N0=86.8%; 5YS LCP with N12=43.4%; P=0.0000 by Log-Rank Test. Complete Censored 0 5 10 15 20 25 30 35 Years after Surgery 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1.0 Cumulative Proportion Surviving LCP with N12 LCP with N0
  • 10. RESULTS OF UNIVARIATE ANALYSIS OF ADJUVANT CHEMOIMMUNORADIOTHERAPY IN PREDICTION OF LUNG CANCER PATIENTS SURVIVAL WITH N1-2 (N=251): Cumulative Proportion Surviving (Kaplan-Meier) LCP with N12 5YS LCP after Adjuvant Treatment=63.4%; 5YS after surgery along=34.8%; P=0.00003 by Log-Rank Test. Complete Censored 0 5 10 15 20 25 30 Years after Surgery 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1.0 Cumulative Proportion Surviving only Surgery Adjuvant Chemoimmunoradiotherapy
  • 11. RESULTS OF UNIVARIATE ANALYSIS OF SURGERY TYPE (LOBECTOMIES VS. PNEUMONECTOMIES) IN PREDICTION OF LUNG CANCER PATIENTS SURVIVAL (N=765): Cumulative Proportion Surviving (Kaplan-Meier) 5YS LCP after Lobectomies=77.6%; 5YS LCP after Pneumonectomies=63%; P=0.00001 by Log-Rank Test. Complete Censored 0 5 10 15 20 25 30 35 Years after Surgery -0.1 0.0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1.0 Cumulative Proportion Surviving LCP after Pneumonectomies LCP after Lobectomies
  • 12. RESULTS OF COX REGRESSION MODELING IN PREDICTION OF LUNG CANCER PATIENTS SURVIVAL AFTER COMPLETE SURGERY (N=756): Cox Parameter Estimate Standard Error Chi- square P value 95% Lower CL 95% Upper CL Hazard Ratio PT N0----N12 1.12860 0.144710 60.82492 0.000000 0.84497 1.4122293.091330 PT Early-Invasive LC -1.47064 0.289169 25.86488 0.000000 -2.03740 -0.9038810.229778 Histology 0.32311 0.083065 15.13080 0.000100 0.16030 0.4859111.381414 Heparin Tolerance 0.00334 0.000653 26.16087 0.000000 0.00206 0.0046221.003347 Recalcification Time -0.00395 0.001693 5.43911 0.019691 -0.00727 -0.0006300.996059 Prothrombin Index 0.03107 0.006560 22.43073 0.000002 0.01821 0.0439241.031555 AT -1.03805 0.196916 27.78926 0.000000 -1.42400 -0.6521060.354143 Leucocytes/CC -0.40957 0.150122 7.44318 0.006368 -0.70380 -0.1153320.663939 Segmented Neut/CC 0.43089 0.162072 7.06844 0.007845 0.11324 0.7485501.538633 Lymphocytes/CC 0.37542 0.172624 4.72960 0.029648 0.03708 0.7137521.455597 G1-3 0.31333 0.087560 12.80502 0.000346 0.14171 0.4849431.367969 Glucose -0.32171 0.077069 17.42452 0.000030 -0.47276 -0.1706540.724911 Thrombocytes tot 0.00055 0.000184 8.94820 0.002777 0.00019 0.0009131.000552 Erythrocytes tot -0.03595 0.016873 4.53860 0.033139 -0.06902 -0.0028760.964691 Age 0.01723 0.008588 4.02430 0.044849 0.00040 0.0340601.017377
  • 13. RESULTS OF NEURAL NETWORKS COMPUTING IN PREDICTION OF LUNG CANCER PATIENTS SURVIVAL AFTER COMPLETE SURGERY (N=698): Corect Classification Rate=100%; Error=0.000; Area under ROC Curve=1.000. Factors, LCP=698 Rank Sensitivity Phase Transition Early—Invasive Cancer 1 28854 Phase Transition N0---N12 2 25420 Thrombocytes/Cancer Cells 3 11601 Erythrocytes/Cancer Cells 4 11414 Eosinophils/Cancer Cells 5 10658 Healthy Cells/Cancer Cells 6 8871 Segmented Neutrophils/Cancer Cells 7 7844 Lymphocytes/Cancer Cells 8 6416 Monocytes/Cancer Cells 9 5454 Stick Neutrophils/Cancer Cells 10 5353 Leucocytes/Cancer Cells 11 4075
  • 14. RESULTS OF BOOTSTRAP SIMULATION IN PREDICTION OF LUNG CANCER PATIENTS SURVIVAL AFTER SURGERY (N=698): Bootstrap Simulation n=698 Significant Factors (Number of Samples=3333) Rank Kendal Tau-A P< Healthy Cells/Cancer Cells 1 -0.297 0.000 Erythrocytes/Cancer Cells 2 -0.293 0.000 Lymphocytes/Cancer Cells 3 -0.287 0.000 Thrombocytes/Cancer Cells 4 -0.268 0.000 Leucocytes/Cancer Cells 5 -0.258 0.000 Segmented Neutrophils/Cancer Cells 6 -0.208 0.000 Tumor Size 7 0.174 0.000 Phase Transition Early-Invasive Cancer 8 -0.163 0.000 Phase Transition N0---N12 9 -0.158 0.000 T1-4 10 0.151 0.000 Prothrombin Index 11 0.141 0.000 Lymphocytes tot 12 -0.140 0.000 Erythrocytes tot 13 -0.138 0.000 Monocytes/Cancer Cells 14 -0.115 0.000 Segmented Neutrophils% 15 0.102 0.000 G1-3 16 0.090 0.001 Lymphocytes% 17 -0.089 0.001 Weight 18 -0.088 0.001 ESS 19 0.086 0.01 Pneumonectomies/Lobectomies 20 -0.067 0.01 Glucose 21 -0.060 0.05 Heparin Tolerance 22 0.060 0.05 Eosinophils/Cancer Cells 23 -0.060 0.05 Eosinophils% 24 -0.055 0.05
  • 15. RESULTS OF KOHONEN SELF-ORGANIZING NEURAL NETWORKS COMPUTING IN PREDICTION OF LUNG CANCER PATIENTS SURVIVAL AFTER SURGERY (N=698):
  • 17. PROGNOSTIC SEPATH-MODEL OF LUNG CANCER PATIENTS SURVIVAL AFTER SURGERY (N=698):
  • 18. 5YS OF LCP AFTER RADICAL PROCEDURES SIGNIFICANTLY DEPENDED ON: 1) PHASE TRANSITION EARLY-INVASIVE CANCER; 2) PHASE TRANSITION N0--N12; 3) CELL RATIO FACTORS; 4) BLOOD CELL CIRCUIT; 5) BIOCHEMICAL FACTORS; 6) HEMOSTASIS SYSTEM; 7) ADJUVANT TREATMENT; 8) LC CHARACTERISTICS; 9) SURGERY TYPE: LOBECTOMY/PNEUMONECTOMY; 10) ANTHROPOMETRIC DATA. Conclusion:
  • 19. OLEG KSHIVETS, M.D.,PH.D. CONSULTANT THORACIC, ABDOMINAL, GENERAL SURGEON & SURGICAL ONCOLOGIST  e-mail: okshivets@yahoo.com  skype: okshivets  http: //www.ctsnet.org/home/okshivets